Trials
9 active
11 in total · 11 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Ischemic Stroke
- Main trialPhase 3
- “This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot. The purpose of this study is to find out whether a medicine called tenecteplase helps people recover from an acute stroke. Tenecteplase is already…”In the company’s words, NCT07361302 on ClinicalTrials.gov
Other drugs for Acute Ischemic Stroke
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up1
- 2 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 2 Oct 2027 | A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | |
| Phase 3Ended | not given | Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion | |
| Phase 3Ended | not given | Early Reperfusion Therapy with Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III trial | |
| Phase 3Authorised | not given | The efficacy and Safety of Intravenous thrombolysis in acute ischemic stroke patients with recent ingestion of Factor Xa-inhibitors Trial (SIFT) | |
| Phase 3Authorised | not given | Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (POST ETERNAL) | |
| Phase 4Authorised | not given | Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The DOAC Intravenous Thrombolysis trial | |
| Phase 2Authorised | not given | Local tenecteplase applicatiOn subsequent to endovasCular recanalization in Anterior circuLation stroke - the LOCAL trial | |
| Phase 3Authorised | not given | TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation) | |
| Phase 3Authorised | not given | “Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trial” THE IVT ALL IN TRIAL | |
| Phase 3Authorised | not given | Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants – a multicentre randomised placebo-controlled clinical trial | |
| Phase 3Authorised | not given | Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026